<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22743" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hemophilia A</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Salen</surname>
            <given-names>Philip</given-names>
          </name>
          <aff>St. Luke's University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Babiker</surname>
            <given-names>Hani M.</given-names>
          </name>
          <aff>University of Arizona Cancer Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Philip Salen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hani Babiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22743.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hemophilia encompasses a group of inherited disorders that alter blood coagulation. Classical hemophilia, also known as hemophilia A, is a hereditary hemorrhagic disorder resulting from a congenital deficit of factor VIII that manifests as protracted and excessive bleeding either spontaneously or secondary to trauma. This activity describes the cause of hemophilia A, reviews its presentation, and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the etiology of hemophilia A.</p></list-item><list-item><p>Outline the common presentation of a patient with hemophilia A.</p></list-item><list-item><p>Review the management options available for hemophilia A.</p></list-item><list-item><p>Explain interprofessional team strategies for improving care coordination and communication to advance the treatment of hemophilia A and improve patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22743&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22743">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22743.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hemophilia, which means love (philia) of blood (hemo), manifests with prolonged and excessive bleeding either spontaneously or after insignificant trauma. Hemophilia&#x000a0;encompasses&#x000a0;a group of&#x000a0;inherited&#x000a0;ailments that&#x000a0;alter the body's normal blood coagulation. A hereditary hemorrhagic disorder resulting from a congenital deficit or scarcity of factor VIII, hemophilia A, which is known as classical hemophilia, manifests as protracted and excessive bleeding either spontaneously or secondary to trauma.<xref ref-type="bibr" rid="article-22743.r1">[1]</xref><xref ref-type="bibr" rid="article-22743.r2">[2]</xref><xref ref-type="bibr" rid="article-22743.r3">[3]</xref></p>
      </sec>
      <sec id="article-22743.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>An&#x000a0;X-linked, recessive hemorrhagic trait or gene induces Hemophilia A.&#x000a0; Hemophilia A's X-linked trait manifests as a congenital absence or decrease in plasma clotting Factor VIII, a pro-coagulation cofactor and robust initiator of thrombin that is essential for the generation of adequate amounts of fibrin to form a platelet-fibrin plug at sites of endothelial disruption. Female Hemophilia A gene carriers will transmit the gene to 50% of their male offspring, who&#x000a0;will inherit the disorder. Female hemophilia gene carriers do not&#x000a0;manifest symptoms of Hemophilia A but may have lower than usual&#x000a0;quantities of Factor VIII. Male Hemophilia A patients do&#x000a0;not transmit hemophilia to male offspring,&#x000a0;but their female offspring&#x000a0;will carry the&#x000a0;hemophilia gene.<xref ref-type="bibr" rid="article-22743.r4">[4]</xref><xref ref-type="bibr" rid="article-22743.r5">[5]</xref><xref ref-type="bibr" rid="article-22743.r6">[6]</xref><xref ref-type="bibr" rid="article-22743.r7">[7]</xref></p>
      </sec>
      <sec id="article-22743.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hemophilia A is the most common X-linked hereditary disorder of hemostasis; it occurs in one out of 5000 males and accounts for 80% of hemophilia cases. Hemophilia A occurs in more than 400000&#x000a0;males worldwide, many of whom remain undiagnosed in the developing world.</p>
      </sec>
      <sec id="article-22743.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>When the vascular endothelium sustains an injury, the hemostatic process initiates the coagulation cascade to restore vascular integrity and prevent further bleeding. Platelet activation&#x000a0;occurs at the site of vascular&#x000a0;rupture, initiating&#x000a0;promulgation&#x000a0;of clotting factors and fibrin formation, resulting in a platelet-fibrin plug to inhibit further bleeding. Factor VIII, the deficit of which causes hemophilia A, provides essential enhancement of thrombin generation and promulgation of fibrin formation to inhibit further bleeding. Factor VIII adheres to von Willebrand factor to protect it from proteolytic degradation. Bleeding in hemophilia results from defective fibrin stabilization secondary to inadequate fibrin generation, which results in a failure of secondary hemostasis. Insufficient thrombin in the coagulation cascade results in a deficiency of fibrin.</p>
      </sec>
      <sec id="article-22743.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Severe hemophilia often manifests in the first months of life, whereas mild or moderate hemophilia will present later in childhood or adolescence, often incidentally or following trauma. In two-thirds of cases, confirmation of the hemophilia diagnosis occurs shortly after the delivery of an affected son to a mother who carries the susceptible gene. In spontaneous mutation scenarios that occur in one-third of cases, hemophilia A diagnostic confirmation proceeds after bleeding symptoms occur spontaneously or after insignificant trauma. Characteristic hemophilia bleeding symptoms can manifest as spontaneous intracranial bleeding in neonates, excessive postoperative bleeding after circumcision, atraumatic painful hemarthrosis,&#x000a0;inexplicable bruising when the infant begins crawling or walking, and inordinate musculocutaneous hemorrhage, either spontaneously or after intramuscular vaccination. Frequent falls or impacts from furniture while learning to ambulate can induce extensive soft tissue contusions and hemorrhage that can mimic the appearance of child abuse in the young hemophiliac. Hemarthrosis manifests as the most common hemorrhagic symptom in adolescents and adults. Recurrent hemarthrosis eventually causes erosion of joint cartilage and results in the painful Charcot joints of hemophilic arthropathy. Intracranial hemorrhage represents the most immediate life-threatening manifestation of hemophilia A with the potential for chronic neurological disability and long-term neurological sequelae.</p>
      </sec>
      <sec id="article-22743.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnostic evaluation for hemophilia occurs in the setting of a known family history, excessive bleeding out of proportion to the traumatic injury, or abnormally activated partial thromboplastin time. Normal hemogram and prothrombin time in the setting of elevated activated partial thromboplastin time heightens the suspicion of hemophilia and should prompt factor VIII and IX determination. Determining residual plasma concentration of factor VIII represents the keystone of diagnosis, classification, and treatment of hemophilia A as therapy and prognosis will vary depending on factor VIII deficiency. Most hemophilia A patients have a prolonged activated partial thromboplastin time; however, a normal result does not rule out mild hemophilia. Hemorrhage severity in hemophilia A correlates with scarcity of factor VIII. Factor VIII concentration is expressed in international units (IU); 1 IU is the concentration of factor VIII in 1 mL of pooled plasma or percentages of normal pooled plasma with normal levels ranging between 50% to 150%. Severe Hemophilia A will have no measurable factor VIII, less than 0.01 IU/mL or less than 1%, and will bleed spontaneously. Moderate or mild hemophilia, 0.02 to 0.05 IU/mL (2% to 5%) or 0.06&#x000a0;IU/mL&#x000a0;to 0.40 IU/mL (6% to 40%), respectively, will bleed excessively after relatively insignificant trauma.</p>
      </sec>
      <sec id="article-22743.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Administration of recombinant factor VIII replacement for the treatment of acute bleeding in severe hemophilia A patients should occur promptly with initiation before completion of the patient assessment. Calculation of factor VIII replacement for bleeding in severe hemophilia A is<xref ref-type="bibr" rid="article-22743.r8">[8]</xref><xref ref-type="bibr" rid="article-22743.r9">[9]</xref><xref ref-type="bibr" rid="article-22743.r10">[10]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose of factor VIII = percentage desired of factor x bodyweight (kg) x 0.5</p>
          </list-item>
        </list>
        <p>For severe, life-threatening hemorrhage, administer factor VIII to achieve a 100% desired factor VIII level; for mild to moderate hemorrhage, administer factor VIII to achieve a 30% to 50% desired&#x000a0;factor VIII level. Accounting for the hemophilia A patient's native factor VIII levels should be factored into factor VIII repletion if known. The combination of effective blood product screening with viral inactivation protocols and recombinant production of Factor VIII has enhanced factor VIII replacement products' safety from viral transmission, such as HIV and hepatitis C.</p>
        <p>Other pharmaceutical&#x000a0;adjuvant therapies for hemophilia A-induced bleeding include desmopressin, tranexamic acid, epsilon aminocaproic acid, and management of factor VIII inhibitors. Intravenous, subcutaneous, or intranasal desmopressin (DDAVP) has utility for the treatment of bleeding in mild to moderate hemophilia A patients by triggering the release of complexes von Willebrand's factor and factor VIII from vascular endothelial cells.</p>
        <p>Periodic, prophylactic Factor VIII concentrates&#x000a0;infusions for patients with severe Hemophilia A have benefits in preventing spontaneous bleeding. The intent of factor VIII prophylaxis aims to modify severe hemophilia to a milder form by keeping the nadir level of factors&#x000a0;more than 1% of normal. The World Federation of Hemophilia recommends factor VIII prophylaxis initiation in hemophiliac children after their first or second episode of hemarthrosis to prevent joint destruction and preserve musculoskeletal function. Mild and moderate hemophilia A patients receive factor VIII concentrates or desmopressin to prevent hemorrhage in anticipation of trauma or surgery.<xref ref-type="bibr" rid="article-22743.r11">[11]</xref><xref ref-type="bibr" rid="article-22743.r12">[12]</xref></p>
      </sec>
      <sec id="article-22743.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acquired hemophilia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ehlers-Danlos syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Factor XI deficiency</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Glanzmann thrombasthenia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Haemophilia C</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Haemophilia type B</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Physical child abuse</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Platelet disorders</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Von Willebrand disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22743.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Defects in the binding of factor VIII and von Willebrand factor, characterizing type 2N or &#x0201c;Normandy type&#x0201d; von Willebrand disease, will manifest like hemophilia-induced bleeding. Still, unlike hemophilia, inherited manifestation occurs in an autosomal pattern, thereby also affecting female patients. Establishing the diagnosis of type 2N von Willebrand disease utilizes molecular genetic testing.</p>
        <p>Many severe hemophilia A patients, nearly 30%, develop alloantibodies against administered factor VIII. Inhibitor development represents a major complication and challenge in hemophilia treatment because these alloantibodies inactivate the procoagulant effect of infused factor VIII, thereby inhibiting the response to factor VIII replacement.</p>
      </sec>
      <sec id="article-22743.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Hemophilia A management is best by an interprofessional team that includes hematology nurses. Once the diagnosis is confirmed based on plasma factor VIII levels, patient and family referral for genetic screening and counseling for factor VIII gene mutation analysis&#x000a0;to&#x000a0;establish carrier status.</p>
        <p>The outlook for most patients with hemophilia A is guarded. Repeated transfusions of blood products and related factors are not benign events. Additionally, these patients are prone to bleeding, which can be life-threatening.</p>
        <p>The pharmacist should perform a thorough medication check, looking for any agents that might precipitate bleeding, as well as verifying dosing of clotting factors and any other medications (eg, pain control.). Nurses can provide patient counseling, report concerns to the managing clinician, and monitor patient progress and status. These interprofessional examples demonstrate how this approach can optimize patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-22743.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22743&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22743">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/hemophilia-a/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22743">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22743/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22743">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22743.s13">
        <title>References</title>
        <ref id="article-22743.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez Fern&#x000e1;ndez</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Limitations of prophylactic treatment in patients with hemophilia.</article-title>
            <source>Blood Coagul Fibrinolysis</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>1S Suppl 1</issue>
            <fpage>S22</fpage>
            <page-range>S22-S24</page-range>
            <pub-id pub-id-type="pmid">31157677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22743.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahlangu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Emicizumab for the prevention of bleeds in hemophilia A.</article-title>
            <source>Expert Opin Biol Ther</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>753</fpage>
            <page-range>753-761</page-range>
            <pub-id pub-id-type="pmid">31150297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22743.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oldenburg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hay</surname>
                <given-names>CRM</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez-Yuste</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Peyvandi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schved</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Szamosi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Winding</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lethagen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.</article-title>
            <source>BMJ Open</source>
            <year>2019</year>
            <month>May</month>
            <day>30</day>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>e028012</fpage>
            <pub-id pub-id-type="pmid">31152037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22743.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ulrich-Merzenich</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hausen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zeitler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goldmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Oldenburg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pavlova</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The role of variant alleles of the mannose-binding lectin in the inhibitor development in severe hemophilia A.</article-title>
            <source>Thromb Res</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>179</volume>
            <fpage>140</fpage>
            <page-range>140-146</page-range>
            <pub-id pub-id-type="pmid">31141731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22743.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tegenge</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mahmood</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Forshee</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacology Review of Plasma-derived and Recombinant Protein Products: CBER Experience and Perspectives on Model-Informed Drug Development.</article-title>
            <source>Haemophilia</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>e240</fpage>
            <page-range>e240-e246</page-range>
            <pub-id pub-id-type="pmid">31131515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22743.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miesbach</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>O'Mahony</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Key</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Makris</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>How to discuss gene therapy for haemophilia? A patient and physician perspective.</article-title>
            <source>Haemophilia</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>545</fpage>
            <page-range>545-557</page-range>
            <pub-id pub-id-type="pmid">31115117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22743.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schep</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Boes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schutgens</surname>
                <given-names>REG</given-names>
              </name>
              <name>
                <surname>van Vulpen</surname>
                <given-names>LFD</given-names>
              </name>
            </person-group>
            <article-title>An update on the 'danger theory' in inhibitor development in hemophilia A.</article-title>
            <source>Expert Rev Hematol</source>
            <year>2019</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>335</fpage>
            <page-range>335-344</page-range>
            <pub-id pub-id-type="pmid">30951401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22743.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Samuelson Bannow</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Recht</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>N&#x000e9;grier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hermans</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berntorp</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Eichler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mancuso</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Klamroth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>O'Hara</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Santagostino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Matsushita</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.</article-title>
            <source>Blood Rev</source>
            <year>2019</year>
            <month>May</month>
            <volume>35</volume>
            <fpage>43</fpage>
            <page-range>43-50</page-range>
            <pub-id pub-id-type="pmid">30922616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22743.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Top</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Geisen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Decker</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Reski</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Critical Evaluation of Strategies for the Production of Blood Coagulation Factors in Plant-Based Systems.</article-title>
            <source>Front Plant Sci</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>261</fpage>
            <pub-id pub-id-type="pmid">30899272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22743.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Preijers</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sch&#x000fc;tte</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Kruip</surname>
                <given-names>MJHA</given-names>
              </name>
              <name>
                <surname>Cnossen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Leebeek</surname>
                <given-names>FWG</given-names>
              </name>
              <name>
                <surname>van Hest</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Math&#x000f4;t</surname>
                <given-names>RAA</given-names>
              </name>
            </person-group>
            <article-title>Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.</article-title>
            <source>Ther Drug Monit</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>192</fpage>
            <page-range>192-212</page-range>
            <pub-id pub-id-type="pmid">30883513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22743.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lasne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pouplard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nougier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eschwege</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Le Cam Duchez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Proulle</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Smahi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harzallah</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Voisin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Toulon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sobas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galinat</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Flaujac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ternisien</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jeanpierre</surname>
                <given-names>E</given-names>
              </name>
              <collab>groupe d'&#x000e9;tudes de la biologie des maladies h&#x000e9;morragiques du Groupe fran&#x000e7;ais d'&#x000e9;tudes de l'h&#x000e9;mostase et la thrombose</collab>
            </person-group>
            <article-title>[Factor VIII assays in treated hemophilia A patients].</article-title>
            <source>Ann Biol Clin (Paris)</source>
            <year>2019</year>
            <month>Feb</month>
            <day>01</day>
            <volume>77</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-65</page-range>
            <pub-id pub-id-type="pmid">30799298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22743.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <article-title>Emicizumab for haemophilia A.</article-title>
            <source>Aust Prescr</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <pub-id pub-id-type="pmid">30765913</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
